GAM
JAZZ icon

Groupama Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Groupama Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$694K Buy
2,921
+345
+13% +$75.6K 0.01% 276
2026
Q1 		$487K Hold
2,576
– – 0.01% 302
2025
Q4 		$438K Hold
2,576
– – 0.01% 355
2025
Q3 		$340K Sell
2,576
-6,142
-70% -$737K 0.01% 404
2025
Q2 		$932K Hold
8,718
– – 0.02% 285
2025
Q1 		$1.07M Buy
8,718
+619
+8% +$80.8K 0.02% 243
2024
Q4 		$996K Buy
8,099
+1,305
+19% +$154K 0.02% 274
2024
Q3 		$608K Buy
6,794
+309
+5% +$33.9K 0.02% 326
2024
Q2 		$692K Sell
6,485
-1,217
-16% -$134K 0.01% 339
2024
Q1 		$933K Sell
7,702
-58,858
-88% -$7.21M 0.02% 320
2023
Q4 		$8.19M Buy
+66,560
New +$8.31M 0.21% 90

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Groupama Asset Management's JAZZ Position: Q2 2026 in Review

Groupama Asset Management increased its Jazz Pharmaceuticals (JAZZ) stake by 13% in Q2 2026, buying an estimated $75.6K and bringing the position to 2,921 shares worth $694K. The position accounts for 0.01% of the portfolio, ranked #276.

Groupama Asset Management first reported a position in JAZZ in Q4 2023 and has held it in 11 quarters since. The position peaked at $8.19M in Q4 2023. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Groupama Asset Management held 2,921 shares of Jazz Pharmaceuticals worth $694K as of Q2 2026.
  • Groupama Asset Management bought 345 Jazz Pharmaceuticals shares in Q2 2026, an estimated $75.6K.
  • Jazz Pharmaceuticals made up 0.01% of Groupama Asset Management's portfolio in Q2 2026, its #276 holding.
  • Groupama Asset Management first reported a position in Jazz Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Groupama Asset Management's Jazz Pharmaceuticals position peaked at $8.19M in Q4 2023.
  • 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Groupama Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.